VV ECMO respiratory failure support offers a critical lifeline for patients who do not respond to traditional mechanical ventilation. Recently, researchers at the National Institute of Cardiology Ignacio Chávez (INCICh) shared five years of clinical data regarding their cardiovascular intensive care unit. Their findings reveal a promising 70% in-hospital survival rate among patients with severe respiratory distress. This result exceeds many previously reported international benchmarks for similar critical care settings. Primarily, the medical team utilized venovenous extracorporeal membrane oxygenation (VV-ECMO) for SARS-CoV-2 related failures.

Optimizing Outcomes in VV ECMO Respiratory Failure

Interestingly, comorbidities and anthropometric variables showed no significant association with mortality rates in this specific cohort. However, non-survivors typically experienced longer stays in the intensive care unit and required extended mechanical ventilation. Furthermore, acute kidney injury appeared as the most frequent complication during the support period. Despite its high frequency, renal failure did not directly correlate with an increased risk of death. Therefore, specialized protocols and dedicated multidisciplinary teams play a vital role in managing these complex cases. Consequently, clinical centers must establish rigorous selection criteria to ensure the best possible outcomes for their patients.

Frequently Asked Questions

What is the typical survival rate for VV ECMO respiratory failure?

While international registries often report survival rates between 50% and 60%, specialized centers with established protocols have achieved rates as high as 70% in recent years.

What are the most common complications of VV ECMO?

Acute kidney injury is frequently cited as the most common complication. Other risks include bleeding at the cannulation site, infection, and thrombosis, which require constant monitoring by the ICU team.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Manzur-Sandoval D et al. [Five years of VV ECMO for severe respiratory failure in a Latin American cardiovascular center]. Arch Cardiol Mex. 2026 Apr 07. doi: 10.24875/ACM.25000234. PMID: 41945927.

ELSO Registry Reports. Extracorporeal Life Support Organization (ELSO). International Summary and Outcomes Statistics.

Lorusso R et al. Evolving outcomes of extracorporeal membrane oxygenation during the COVID-19 pandemic. Lancet Respir Med. 2021.